NASDAQ:GDTC CytoMed Therapeutics (GDTC) Stock Price, News & Analysis $1.16 +0.28 (+31.79%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.05 -0.11 (-9.48%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About CytoMed Therapeutics Stock (NASDAQ:GDTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytoMed Therapeutics alerts:Sign Up Key Stats Today's Range$0.95▼$1.1750-Day Range$0.76▼$1.1652-Week Range$0.68▼$3.68Volume93,017 shsAverage Volume14,136 shsMarket Capitalization$13.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore. Read More CytoMed Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreGDTC MarketRank™: CytoMed Therapeutics scored higher than 7% of companies evaluated by MarketBeat, and ranked 851st out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCytoMed Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCytoMed Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CytoMed Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCytoMed Therapeutics has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.58% of the float of CytoMed Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytoMed Therapeutics has a short interest ratio ("days to cover") of 11.22, which indicates bearish sentiment.Change versus previous monthShort interest in CytoMed Therapeutics has recently decreased by 5.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytoMed Therapeutics does not currently pay a dividend.Dividend GrowthCytoMed Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.67 News SentimentCytoMed Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CytoMed Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for GDTC on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytoMed Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions0.04% of the stock of CytoMed Therapeutics is held by institutions.Read more about CytoMed Therapeutics' insider trading history. Receive GDTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GDTC Stock News HeadlinesCytoMed Renames Subsidiary to Drive Asian and International ExpansionMay 11, 2026 | tipranks.comCytoMed Therapeutics Sets May 22, 2026 AGM With Expanded Share-Issuance Mandate on the TableApril 14, 2026 | tipranks.comHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall of Fame Trader Jon Najarian now says EVERYONE is missing an even bigger story about the SpaceX IPO… That it's just the start of an Elon Musk $44 trillion "Superconvergence…" An event that could kick off as soon as June 9th.May 16 at 1:00 AM | Banyan Hill Publishing (Ad)CytoMed Therapeutics Widens 2025 Loss as It Accelerates Cell Therapy Trials and Southeast Asia ExpansionMarch 31, 2026 | tipranks.comCytoMed Therapeutics Refutes Misleading Claims, Confirms Ongoing First-in-Human TrialJanuary 28, 2026 | tipranks.comCytoMed Therapeutics Addresses Inaccurate Claims About Its Research and Clinical ProgressJanuary 28, 2026 | quiverquant.comQCytoMed Therapeutics Limited Partners with UMMC to Launch First-in-Human Phase I Clinical Trial for Allogeneic γδ T Cell Immunotherapy in MalaysiaDecember 8, 2025 | quiverquant.comQCytoMed Therapeutics Partners with Malaysian Hospital for Groundbreaking Cancer TrialDecember 8, 2025 | tipranks.comSee More Headlines GDTC Stock Analysis - Frequently Asked Questions How have GDTC shares performed this year? CytoMed Therapeutics' stock was trading at $1.3350 at the start of the year. Since then, GDTC shares have decreased by 13.1% and is now trading at $1.16. How were CytoMed Therapeutics' earnings last quarter? CytoMed Therapeutics Limited (NASDAQ:GDTC) issued its quarterly earnings data on Sunday, February, 15th. The company reported ($0.06) EPS for the quarter. The firm had revenue of $0.06 million for the quarter. When did CytoMed Therapeutics IPO? CytoMed Therapeutics (GDTC) raised $11 million in an IPO on Wednesday, April 12th 2023. The company issued 2,412,369 shares at a price of $4.00-$5.00 per share. How do I buy shares of CytoMed Therapeutics? Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytoMed Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytoMed Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU). Company Calendar Last Earnings2/15/2026Today5/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 GDTC's financial health is in the Red zone, according to TradeSmith. GDTC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GDTC CIK1873093 Webw2.cytomed.sg Phone65-6250-7738FaxN/AEmployeesN/AYear Founded2018Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.06 Current Ratio5.17 Quick Ratio5.17 Sales & Book Value Annual Sales$250 thousand Price / Sales54.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book2.58Miscellaneous Outstanding Shares11,830,000Free FloatN/AMarket Cap$13.72 million OptionableNot Optionable Beta-0.18 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GDTC) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredTrump Just Named His Secret AI Project. It's Called "Golden Dawn."Behind a hidden government lab in Tennessee, 40,000 scientists are reportedly finishing work on an AI system d...InvestorPlace | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrading legend: “I made millions for CEO clients just repeating this 1 secret”TradeSmith Senior Analyst Jeff Clark has guided readers through 300-plus winning trades over 9 years - across ...TradeSmith | SponsoredThe gold strategy that works whether prices rise or fallFormer $900 million hedge fund manager Larry Benedict has developed a strategy he calls Gold Skimming - a way ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
